Indian companies have made acquisitions of $1 billion so far in January
Real estate will prosper, small developers won't.
Sale of antibiotics is under the scanner. Government to go tough on misuse of these drugs.
First case filed after new norms come into force, NCLT admits plea.
Delhi-based Nilesh Sharma, among the first IPs, said while the framework is in the initial stage and might have teething trouble, the opportunity is immense in the long run.
The National Stock Exchange's proposed IPO to raise Rs 10,000 crore this year is expected to see the largest ever PE exit, of around Rs 5,000 crore.
Cross previous high of $72 billion in 2007 as Indian promoters overcome the selling taboo. Abhineet Kumar reports from Mumbai.
Increase of 10% to 12% likely in a bid to improve citizens' mood after demonetisation.
4,000 dialysis units to be set up across India, government working on providing free basic healthcare to BPL families.
Accumulated sum Rs 31,500 crore in 2015-16
The central government has drafted a law to restrict wombs for hire, and there is much to be said on all sides.
The venture is applying to the Reserve Bank of India for approvals.
The Aditya Birla Group announced the merger of its two holding companies, Aditya Birla Nuvo and Grasim, to make the holding structure clearer, ensure stable cash flows and unlock value in its financial services arm
Sixteen companies in the group registered a turnover of over $500 million, with ten of these registering a turnover of over $1 billion
The founders of Gland Pharma, led by Ravi Penmetsa, and KKR, together own 96 per cent of the company.
Ahmedabad-based firm to fund deal through equal amount of equity and debt.
Unlike last year, investors turn cautious on e-commerce sector.
The numbers in India may not be as big but the opportunity for serious growth is all there.
The sale is to generate the bail money for the release of Sahara Group chief Subrata Roy.
© 2025 Rediff.com - Investor Information - Advertise with us - Disclaimer - Privacy Policy - Sitemap - Feedback - About us - Terms of use - Grievances